Clinical Trial Update: Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing WX-0593 to crizotinib in ALK-positive non-small cell lung cancer is underway, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• WX-0593

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN